Volastra: FDA Grants Fast Track Status to VLS-1488 for Platinum-Resistant High-Grade Serous Ovarian Cancer
The KIF18A inhibitor VLS-1488 has received fast track designation from the FDA for platinum-resistant high-grade serous ovarian cancer.
Read full article »
Volastra is a New York-based clinical-stage biotechnology company that researches and develops novel therapies for the treatment of cancer.
Read more